We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolomic Profile Predicts Type II Diabetes Risk for Normal Weight Individuals

By LabMedica International staff writers
Posted on 05 May 2022

Employing a metabolomics approach, a team of Swedish investigator identified a panel of metabolites linked to obesity and found that normal weight individuals with this metabolic profile had increased risk for Type II diabetes and all-cause mortality compared with lean individuals with a healthy metabolome. More...

The "metabolome" includes four major classes of biological molecules: lipids, proteins/amino-acids, sugars, and nucleic acids.

Obesity is a key risk factor for Type II diabetes; however, up to 20% of diabetes patients are normal weight. Therefore, investigators aimed to identify metabolite patterns that were reproducibly predictive of BMI (body mass index) and subsequently to test whether lean individuals who expressed an obese metabolome were at hidden high risk of obesity-related diseases, such as Type II diabetes.

BMI is a measure of body fat based on height and weight, which is used to evaluate if a person is underweight, of normal weight, or obese. To determine whether they could identify a BMI-linked metabolome, investigators at Lund University (Sweden) measured levels of 108 metabolites associated with Type II diabetes in plasma samples from 7,663 individuals from two Swedish and one Italian population-based cohort. Ridge regression was used to predict BMI using the metabolites.

Individuals with a predicted BMI either higher (overestimated) or lower (underestimated) than their actual BMI were characterized as outliers and further investigated for obesity-related risk factors and future risk of Type II diabetes and mortality.

The participants were divided into five groups based on the relationship between the BMI linked to weight and height and their metabolic BMI. The five groups were (1) individuals with a normal BMI based on weight, height, and metabolism; (2) overweight individuals based on weight, height, and metabolism; (3) obese individuals based on weight, height, and metabolism. (4) Individuals in this group had a normal BMI based on height and weight. Their metabolic BMI had metabolic alterations associated with obesity. (5) Individuals in this group had a metabolic BMI which was lower than their BMI based on weight and height.

Results revealed that the metabolome could predict BMI in all cohorts. The overestimated group had a BMI similar to individuals correctly predicted as normal weight, had a similar waist circumference, were not more likely to change weight over time, but had a two times higher risk of future Type II diabetes and an 80% increased risk of all-cause mortality. These associations remained after adjustments for obesity-related risk factors and lifestyle parameters.

Senior author Dr. Olle Melander, professor of internal medicine at Lund University, said, “We hope that our research will be used to identify individuals with a hidden risk of developing the disease. If we can find these individuals before the disease debuts, we would be able to initiate preventive actions. This could potentially save society a lot of money as Type II diabetes often leads to a variety of different complications.”

The study was published in the March 14, 2022, online edition of the journal Diabetes Care.

Related Links:
Lund University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.